Amgen (AMGN) announced that Howard Chang will join the company as Senior VP of Research, effective Dec. 16. Chang will also assume the title and responsibility of serving as Amgen’s Chief Scientific Officer, reporting to Jay Bradner, , EVP of Research and Development. Chang succeeds Ray Deshaies, former SVP of Research, whose departure was announced earlier this year.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AMGN:
- Viridian Therapeutics (VRDN) Has Captured Investors’ Attention with Recent Breakthroughs
- Wolfe Research starts Amgen at Peer Perform given approaching patent cliffs
- Amgen initiated with a Peer Perform at Wolfe Research
- Amgen’s Uplizna shows potential efficacy in rare inflammatory diseases
- Amgen call volume above normal and directionally bullish
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
